Last Updated: June 26, 2024
pharmabelgium-belmedis.be has 4 NS records, 2 A records, 0 AAAA records, 2 MX records, and 6 TXT records. Name servers for pharmabelgium-belmedis.be are ns1.openprovider.nl, ns5.pbc.be, ns3.pbc.be, ns4.pbc.be. A records for pharmabelgium-belmedis.be are 45.60.85.130, 45.60.76.130. MX records that process @pharmabelgium-belmedis.be email are mail01.phoenixgroup.eu, mail02.phoenixgroup.eu. We have observed pharmabelgium-belmedis.be to have 1 subdomains. A subdomain count of 1 is considered a small digital footprint. Technology that may be in use at pharmabelgium-belmedis.be includes globalsign.
Search DigitalStakeout ASI to find another asset.
45.60.85.130
45.60.76.130
No DNS AAAA records
mail01.phoenixgroup.eu
mail02.phoenixgroup.eu
ns1.openprovider.nl
ns5.pbc.be
ns3.pbc.be
ns4.pbc.be
pharmabelgium-belmedis.be. 600 IN TXT "globalsign-domain-verification=895f534ec70b0a8239dc67e2db646923"
pharmabelgium-belmedis.be. 600 IN TXT "v=spf1 ip4:85.214.57.211 ip4:81.169.197.121 ip4:85.214.175.9 ip4:85.214.175.12 include:_u.pharmabelgium-belmedis.be._spf.smart.ondmarc.com include:sp" "f.icontroller.eu include:spf.lamapoll.de include:spf.protection.outlook.com -all"
pharmabelgium-belmedis.be. 600 IN TXT "jb2sx7s64kj7rgnbtr3k9w8txhbmf7y4"
pharmabelgium-belmedis.be. 600 IN TXT "MS=ms69047913"
pharmabelgium-belmedis.be. 600 IN TXT "globalsign-domain-verification=7560975C0AD1FDFE1E5ED670E46599B0"
pharmabelgium-belmedis.be. 600 IN TXT "globalsign-domain-verification=7672BB0438B53D291CA74BA887061FE4"
pharmabelgium-belmedis.be has 1 subdomains in our inventory.
Microsoft-IIS/10.0
United States
{"data":{"cert_index":925747495,"cert_link":"https:\/\/ct.googleapis.com\/logs\/eu1\/xenon2024\/ct\/v1\/get-entries?start=925747495&end=925747495","leaf_cert":{"all_domains":["*.pharmabelgium-belmedis.be","imperva.com"],"extensions":{"authorityInfoAccess":"CA Issuers - URI:http:\/\/secure.globalsign.com\/cacert\/gsatlasr3dvtlsca2024q1.crt\nOCSP - URI:http:\/\/ocsp.globalsign.com\/ca\/gsatlasr3dvtlsca2024q1\n","authorityKeyIdentifier":"keyid:66:C0:C7:A3:9A:CD:FE:F3:EA:CE:4B:53:0B:61:5E:AF:33:05:B3:E1\n","basicConstraints":"CA:FALSE","certificatePolicies":"Policy: 1.3.6.1.4.1.4146.10.1.3\n CPS: https:\/\/www.globalsign.com\/repository\/","crlDistributionPoints":"Full Name:\n URI:http:\/\/crl.globalsign.com\/ca\/gsatlasr3dvtlsca2024q1.crl","ctlPoisonByte":true,"extendedKeyUsage":"TLS Web server authentication, TLS Web client authentication","keyUsage":"Digital Signature, Key Encipherment","subjectAltName":"DNS:imperva.com, DNS:*.pharmabelgium-belmedis.be","subjectKeyIdentifier":"32:6A:50:1F:D8:8C:9C:4F:D9:87:62:73:BC:F4:89:25:66:C5:18:77"},"fingerprint":"5E:F1:F1:56:00:21:FD:06:35:A2:8E:04:F9:DE:69:99:23:3D:40:78","issuer":{"C":"BE","CN":"GlobalSign Atlas R3 DV TLS CA 2024 Q1","L":null,"O":"GlobalSign nv-sa","OU":null,"ST":null,"aggregated":"\/C=BE\/CN=GlobalSign Atlas R3 DV TLS CA 2024 Q1\/O=GlobalSign nv-sa","emailAddress":null},"not_after":1705581961,"not_before":1705495561,"serial_number":"13331AB9BEC778149AFFDE6E04B870A","signature_algorithm":"sha256, rsa","subject":{"C":null,"CN":"imperva.com","L":null,"O":null,"OU":null,"ST":null,"aggregated":"\/CN=imperva.com","emailAddress":null}},"seen":1705495787.908805,"source":{"name":"Google 'Xenon2024' log","url":"https:\/\/ct.googleapis.com\/logs\/eu1\/xenon2024\/"},"update_type":"PrecertLogEntry"},"message_type":"certificate_update"}